Seer, Inc. is a life sciences company. It is developing products that open a new gateway to the proteome. Its Proteograph product suite is an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation and software to perform proteomic analysis at scale in a matter of hours. The Proteograph has detected over 36,000 proteins across multiple species, and its performance and capabilities have been demonstrated in over 33 peer-reviewed publications, preprints and reviews. The Proteograph Product Suite is detector-agnostic and is adaptable to other protein detection instruments. The MS component of the Proteograph workflow is either provided by the researcher’s laboratory, can be outsourced to a third-party provider, or be run through the Seer Technology Access Center (STAC), which is its in-house service program. It has launched Proteograph XT, which enhances the sample throughput of the Proteograph Product Suite and MS instrument.
BörsenkürzelSEER
Name des UnternehmensSeer Inc
IPO-datumDec 04, 2020
CEOFarokhzad (Omid C)
Anzahl der mitarbeiter134
WertpapierartOrdinary Share
GeschäftsjahresendeDec 04
Addresse3800 Bridge Parkway, Suite 102
StadtREDWOOD CITY
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl94065
Telefon16504530000
Websitehttps://seer.bio/
BörsenkürzelSEER
IPO-datumDec 04, 2020
CEOFarokhzad (Omid C)
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten